Comparison of the effects of diets rich in stearic acid versus myristic acid and lauric acid on platelet fatty acids and excretion of thromboxane A2 and PGI2 metabolites in healthy young men.
The present study compared the effects of diets rich in stearic acid (C18:0) versus one high in lauric and myristic acid (C12:0, C14:0) on platelet phospholipid fatty acid levels and concentrations of urinary thromboxane B2 (TXB2) and 6-keto-PGF1 alpha, which are stable metabolites of thromboxane A2 (TXA2) and PGI2 and indicators of cardiovascular hemostasis. A diet high in dairy butter (B) was the source of C12:0 and C14:0; C18:0 was provided by diets high in cocoa butter (CB), milk chocolate (CHOC) or CB+B in a 4:1 ratio (MIX). A randomized, crossover double-blind experimental design was used. Experimental subjects (n = 15) consumed each diet for 26 days, with a 1-month washout period between each experimental period. Urine and blood were collected from each subject at the beginning and end of each dietary period. Urinary TXB2 and 6-keto-PGF1 alpha were analyzed by radioimmunoassay (RIA). There were no effects of diet on the 24-hour excretion of either metabolite or on the ratio of 6-keto-PGF1 alpha/TXB2, even though there were significant changes in the eicosanoid precursor, arachidonic acid (C20:4n-6), in platelet phospholipids. C20:4n-6 levels increased (44.8% +/- 1.0% to 47.1% +/- 1.3%; P < .05) in the phosphatidylethanolamine phospholipid subclass in subjects on the B diet and decreased in the phosphatidylcholine subclass on the CB diet (16.5% +/- 1.0% to 14.2% +/- 1.1%; P < .05) compared with baseline values.(ABSTRACT TRUNCATED AT 250 WORDS)
Mustad
V A
VA
Graduate Program in Nutrition, Pennsylvania State University, University Park 16802.
Kris-Etherton
P M
PM
Derr
J
J
Reddy
C C
CC
Pearson
T A
TA
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002079:Butter; D002099:Cacao; D004041:Dietary Fats / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D011464:Epoprostenol / Q000652:urine*; D005227:Fatty Acids / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D007231:Infant, Newborn; D007850:Lauric Acids / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D019814:Myristic Acid; D009227:Myristic Acids / Q000008:administration & dosage / Q000494:pharmacology; D010713:Phosphatidylcholines / Q000097:blood; D010714:Phosphatidylethanolamines / Q000097:blood; D013229:Stearic Acids / Q000008:administration & dosage / Q000494:pharmacology; D013928:Thromboxane A2 / Q000652:urine*; D013929:Thromboxane B2 / Q000652:urine
D004041:Dietary Fats; D005227:Fatty Acids; D007850:Lauric Acids; D009227:Myristic Acids; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D013229:Stearic Acids; D019814:Myristic Acid; C030358:lauric acid; C031183:stearic acid; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D002079:Butter; D011464:Epoprostenol